Plans for exploring the effects of bermekimab as a combination therapy in oncology are ongoing. Bermekimab’s strong potential as a combination therapy was highlighted in a commentary piece which accompanied the most recent Lancet Publication. The commentary noted that combining agents that target inflammation, such as bermekimab, with first and second lines of therapy could improve outcomes and survival in advanced cancer patients. Furthermore, given the excellent safety profile of bermekimab, combining it with chemotherapy and/or biological agents are promising options given the recruitment of anti-tumor inflammatory cells seen in patients refractory to these drugs. XBiotech is currently exploring options to assess the potential of bermekimab in combination with other treatments including chemotherapy, EGFR inhibitors and immune check point inhibitors.
XBiotech is currently supporting a physician-sponsored clinical research study headed by Dr. Andrew Hendifar, MD, at Cedars-Sinai Medical Center. The study is being conducted to examine the safety of bermekimab in combination with Onivyde (nanoliposomal irinotecan) and 5- fluorouracil (5FU)/folinic acid (leucovorin) for pancreatic cancer patients suffering from cachexia. In a large randomized study in advanced cancer patients treated with bermekimab, patients experienced increased lean body mass after treatment. This increase could lead to improved weight maintenance and quality of life in pancreatic cancer patients. The study will therefore evaluate whether a correlation between cachexia, activity, and quality of life exists for patients receiving the bermekimab therapy.